We are live on ! Find out more
ERNAW

Ernexa Therapeutics Warrants
ERNAW

6 hedge funds and large institutions have $202K invested in Ernexa Therapeutics Warrants in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding

Funds holding: 5 → 6 (+1)

4% more capital invested

Capital invested by funds: $195K → $202K (+$6.98K)

29.16% less ownership

Funds ownership: 50.02% → 20.86% (-29%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$5.49K
2
CS
Clear Street
New York
+$19

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$364K
2
WAM
Warberg Asset Management
Illinois
-$17.5K

ERNAW Hedge Fund Activity: Q2 2026 in Review

6 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Ernexa Therapeutics Warrants (ERNAW) for Q2 2026, worth a combined $202K — up 3.6% from $195K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ERNAW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $5.49K. The largest seller was Armistice Capital, cutting an estimated $364K.

  • 6 institutional investors held Ernexa Therapeutics Warrants (ERNAW) as of Q2 2026, up from 5 in Q1 2026.
  • Funds reported $202K of Ernexa Therapeutics Warrants stock for Q2 2026, up 3.6% quarter-over-quarter.
  • 1 fund opened new Ernexa Therapeutics Warrants positions in Q2 2026 and 0 closed out, a net change of +1 holder.
  • The largest Ernexa Therapeutics Warrants buyer in Q2 2026 was Susquehanna International Group, an estimated $5.49K added.
  • The largest Ernexa Therapeutics Warrants seller in Q2 2026 was Armistice Capital, an estimated $364K sold.

Based on aggregated 13F filings for Q2 2026.